Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Completed Phase 2 Interventional

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 23, 2026, 4:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

HPV Ends Here: Increasing Uptake of the HPV Vaccine

NCT06831929
View directory record Official record
Conditions
HPV Vaccine
Interventions
Intervention Arm
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
10 Years to 12 Years
Enrollment
2,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

NCT02130869
View directory record Official record
Conditions
Neuroblastoma, Lymphoma, High-risk Tumor
Interventions
CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS
Biological · Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Irritation Potential of Products in Human Eyes.

NCT02728856
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Spray SPF50 Z15-034(BAY987516), Shampoo Control, Sunscreen Spray SPF50 Z15-038(BAY987516)
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

NCT02661373
View directory record Official record
Conditions
Malaria
Interventions
SJ733, Cobicistat
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome

NCT03355469
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Metformin, Placebo, Low Intensity Exercise, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
40 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

NCT02782741
View directory record Official record
Conditions
Glycogen Storage Disease Type II;Pompe's Disease
Interventions
Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
3 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed No phase listed Observational

Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients

NCT00460122
View directory record Official record
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

NCT02266394
View directory record Official record
Conditions
Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
Interventions
Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Not listed No phase listed Observational

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia

NCT01626105
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
Victor J Marder, M.D.
Other
Eligibility
2 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 23, 2026, 4:51 AM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Terminated Not applicable Interventional Results available

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

NCT02718131
View directory record Official record
Conditions
NF1, Congenital Pseudarthrosis of Tibia
Interventions
INFUSE Bone Graft (BMP-2), Control Group
Device · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

NCT04269031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Training Intervention to Improve Mental Health Treatment Effectiveness and Engagement for Youth With Documented Mental Health Disparities

NCT05626231
View directory record Official record
Conditions
Knowledge, Attitudes, Practice
Interventions
Training Intervention
Behavioral
Lead sponsor
Boston College
Other
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Not applicable Interventional

IVF Clinical Trial of Two Different Treatment Protocols.

NCT00799929
View directory record Official record
Conditions
Infertility
Interventions
in vitro fertilization (IVF/ICSI)
Other
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 23, 2026, 4:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Factors Validation and Usability Testing of the IKE Age-Gating System

NCT06952569
View directory record Official record
Conditions
Vaping, Underage
Interventions
IKE System
Other
Lead sponsor
IKE Tech
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 4:51 AM EDT